Full Breakdown
WHO Launches First Ebola Vaccine Trial Amid Expanding Outbreak in the Democratic Republic of Congo
By Drooid · · How we work
Core Event
On Oct 23 the World Health Organization (WHO) announced the start of the “Tumaini” clinical trial in Bunia, Ituri province, DRC. The trial uses the approved Ervebo vaccine—originally for the Zaire strain—to assess cross-protection against the Bundibugyo strain driving the current outbreak.
Background & Context
The DRC declared its 17th Ebola outbreak on May 15, prompting WHO to declare a public health emergency two days later. By the trial launch the outbreak had produced more than 9,600 confirmed cases and over 4,600 deaths, spreading to four African regions.
Trial Design and Candidate Vaccines
Tumaini employs a ring-vaccination approach, immunising high-risk contacts. It will evaluate two Bundibugyo-specific candidates: a ChAdOx1 adenoviral-vector vaccine from the University of Oxford and an mRNA vaccine from Moderna, both funded by CEPI and slated to enter the trial “shortly.” The study also includes pregnant women and children aged 12 years and older.
Data & Statistics
- Confirmed DRC cases between Sept 29 and Oct 19 rose 10.4 % to 1,466, with deaths up 7.5 % to 692.
- As of Oct 19, the DRC recorded 9,637 cases and 4,646 deaths across eight provinces.
- Kenya reported nine cases linked to an imported infection; Nigeria confirmed a case on Oct 20 involving a Swiss diplomat’s wife.
Official Statements & Responses
WHO’s Africa Regional Office noted a modest upward trend in the seven-day moving average, indicating renewed transmission intensity.
CEPI said Tumaini will collaborate with communities, health authorities and response partners to generate evidence on vaccine performance.
Dr Chikwe Ihekweazu, WHO emergencies director, called the trial an “important step” for obtaining rigorous evidence on efficacy against Bundibugyo.
On-the-Ground Reports
Steve Ahuka-Mundeke, DRC Ebola response incident manager, said integrating the trial into the response addresses urgent community needs.
Impact and Regional Concerns
The trial’s outcomes could shape future responses across Central, Eastern and Western Africa, where the Bundibugyo strain has crossed borders. Africa CDC Director-General Jean Kaseya warned of an “extremely serious threat” and urged immediate international action.
Verbatim Quotes
- “Bringing this trial into the Ebola response is an important step towards addressing the urgent needs of affected communities,” — Steve Ahuka-Mundeke
Conflicting Reports & Gaps
Swiss authorities denied that the diplomat’s wife traveled to the DRC, contradicting Ugandan claims that she visited the outbreak zone before returning via Uganda. WHO and Africa CDC have not confirmed the travel route.
What’s Next
CEPI and trial sponsors plan to introduce the two Bundibugyo-specific candidates into the Tumaini framework “shortly,” pending safety and efficacy data. WHO will continue monitoring the outbreak and update guidance based on trial results.